Research ArticleOriginal Research

Diagnostic Utility of Biomarkers in COPD

Vivek N Ambade, Alka N Sontakke, MS Barthwal, R Tyagi and Dashrath R Basannar
Respiratory Care December 2015, 60 (12) 1729-1742; DOI: https://doi.org/10.4187/respcare.03753

References

  1. 1.↵
    1. Rabe KF,
    2. Hurd S,
    3. Anzueto A,
    4. Barnes PJ,
    5. Buist SA,
    6. Calverley P,
    7. et al
    . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176(6):532–555.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Murray CJ,
    2. Lopez AD
    . Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet 1997;349(9064):1498–1504.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Mathers CD,
    2. Loncar D
    . Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3(11):e442.
    OpenUrlCrossRefPubMed
  4. 4.↵
    American Thoracic Society, European Respiratory Society. Standards for the diagnosis and management of patients with COPD. http://www.thoracic.org/clinical/copd-guidelines/resources/copddoc.pdf. Accessed October 24, 2014.
  5. 5.↵
    1. Celli BR,
    2. MacNee W
    . Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS. Eur Respir J 2004;23(6):932–946.
    OpenUrlFREE Full Text
  6. 6.↵
    Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2014. http://www.goldcopd.org/uploads/users/files/GOLD_Report2014_Feb07.pdf. Accessed October 24, 2014.
  7. 7.↵
    1. Pauwels RA,
    2. Buist AS,
    3. Calverley PM,
    4. Jenkins CR,
    5. Hurd SS
    , GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001;163(5):1256–1276.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Falaschetti E,
    2. Swanney MP,
    3. Crapo RO,
    4. Hankinson JL,
    5. Jensen RL,
    6. Pedersen OF,
    7. et al
    . Diagnosis of COPD. Thorax 2007;62(10):924–925; author reply 925.
    OpenUrlFREE Full Text
  9. 9.↵
    1. Viegi G,
    2. Pedreschi M,
    3. Pistelli F,
    4. Di Pede F,
    5. Baldacci S,
    6. Carrozzi L,
    7. Giuntini C
    . Prevalence of airways obstruction in a general population: ERS vs ATS definition. Chest 2000;117(5 Suppl 2):339S–345S.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Lindberg A,
    2. Eriksson B,
    3. Larsson LG,
    4. Rönmark E,
    5. Sandström T,
    6. Lundbäck B
    . Seven-year cumulative incidence of COPD in an age-stratified general population sample. Chest 2006;129(4):879–885.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    1. Bolton CE,
    2. Ionescu AA,
    3. Edwards PH,
    4. Faulkner TA,
    5. Edwards SM,
    6. Shale DJ
    . Attaining a correct diagnosis of COPD in general practice. Respir Med 2005;99(4):493–500.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.
    1. Enright PL,
    2. Crapo RO
    . Controversies in the use of spirometry for early recognition and diagnosis of chronic obstructive pulmonary disease in cigarette smokers. Clin Chest Med 2000;21(4):645–652.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.
    1. Ferguson GT,
    2. Enright PL,
    3. Buist AS,
    4. Higgins MW
    . Office spirometry for lung health assessment in adults: a consensus statement from the National Lung Health Education Program. Chest 2000;117(4):1146–1161.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.
    1. Schermer T,
    2. Eaton T,
    3. Pauwels R,
    4. van Weel C
    . Spirometry in primary care: is it good enough to face demands like World COPD Day? Eur Respir J 2003;22(5):725–727.
    OpenUrlFREE Full Text
  15. 15.↵
    1. Schermer TR,
    2. Jacobs JE,
    3. Chavannes NH,
    4. Hartman J,
    5. Folgering HT,
    6. Bottema BJ,
    7. van Weel C
    . Validity of spirometric testing in a general practice population of patients with chronic obstructive pulmonary disease. Thorax 2003;58(10):861–866.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Haynes JM
    . Pulmonary function test quality in the elderly: a comparison with younger adults. Respir Care 2014;59(1):16–21.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Hardie JA,
    2. Buist AS,
    3. Vollmer WM,
    4. Ellingsen I,
    5. Bakke PS,
    6. Mørkve O
    . Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J 2002;20(5):1117–1122.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Halliwell B
    . Antioxidants in human health and disease. Annu Rev Nutr 1996;16:33–50.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.
    1. MacNee W
    . Treatment of stable COPD: antioxidants. Eur Respir Rev 2005;14(94):12–22.
    OpenUrlAbstract/FREE Full Text
  20. 20.
    1. Diplock AT,
    2. Charleux JL,
    3. Crozier-Willi G,
    4. Kok FJ,
    5. Rice-Evans C,
    6. Roberfroid M,
    7. et al
    . Functional food science and defence against reactive oxidative species. Br J Nutr 1998;80(Suppl 1):S77–S112.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Halliwell B,
    2. Gutteridge JM
    . Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol 1990;186:1–85.
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.↵
    1. Rahman I
    . The role of oxidative stress in the pathogenesis of COPD implications for therapy. Treat Respir Med 2005;4(3):175–200.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Malhotra D,
    2. Thimmulappa R,
    3. Navas-Acien A,
    4. Sandford A,
    5. Elliott M,
    6. Singh A,
    7. et al
    . Decline in NRF2-regulated antioxidants in chronic obstructive pulmonary disease lungs due to loss of its positive regulator, DJ-1. Am J Respir Crit Care Med 2008;178(6):592–604.
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    1. Lacoma A,
    2. Prat C,
    3. Andreo F,
    4. Domínguez J
    . Biomarkers in the management of COPD. Eur Respir Rev 2009;18(112):96–104.
    OpenUrlAbstract/FREE Full Text
  25. 25.
    1. Kim V,
    2. Rogers TJ,
    3. Criner GJ
    . New concepts in the pathobiology of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008;5(4):478–485.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Dickens JA,
    2. Miller BE,
    3. Edwards LD,
    4. Silverman EK,
    5. Lomas DA,
    6. Tal-Singer R
    . COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respir Res 2011;12:146.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Dahl M
    . Biomarkers for chronic obstructive pulmonary disease: surfactant protein D and C-reactive protein. Am J Respir Crit Care Med 2008;177(11):1177–1178.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Turino GM
    . COPD and biomarkers: the search goes on. Thorax 2008;63(12):1032–1034.
    OpenUrlFREE Full Text
  29. 29.↵
    1. Dahl M,
    2. Nordestgaard BG
    . Markers of early disease and prognosis in COPD. Int J Chron Obstruct Pulmon Dis 2009;4:157–167.
    OpenUrlPubMed
  30. 30.↵
    1. Miller MR,
    2. Hankinson J,
    3. Brusasco V,
    4. Burgos F,
    5. Casaburi R,
    6. Coates A,
    7. et al
    . Standardisation of spirometry. Eur Respir J 2005;26(2):319–338.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2010. http://www.goldcopd.org/uploads/users/files/GOLDReport_April112011.pdf. Accessed October 24, 2014.
  32. 32.↵
    1. Jindal SK,
    2. Malik SK
    . Smoking index—a measure to quantify cumulative smoking exposure. Lung India 1988;6(4):195–196.
    OpenUrl
  33. 33.↵
    1. Somani BL,
    2. Ambade V
    . A kinetic method amenable to automation for ceruloplasmin estimation with inexpensive and stable reagents. Clin Biochem 2007;40(8):571–574.
    OpenUrlPubMed
  34. 34.↵
    1. Qaseem A,
    2. Wilt TJ,
    3. Weinberger SE,
    4. Hanania NA,
    5. Criner G,
    6. van der Molen T,
    7. et al
    . Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011;155(3):179–191.
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.↵
    1. Lock-Johansson S,
    2. Vestbo J,
    3. Sorensen G
    . Surfactant protein D, Club cell protein 16, pulmonary and activation-regulated chemokine, C-reactive protein, and fibrinogen biomarker variation in chronic obstructive lung disease. Respir Res 2014;15(1):147.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Bowler RP
    . Surfactant protein D as a biomarker for chronic obstructive pulmonary disease. COPD 2012;9(6):651–653.
    OpenUrlCrossRef
  37. 37.↵
    1. Sin DD,
    2. Pahlavan PS,
    3. Man SF
    . Surfactant protein D: a lung specific biomarker in COPD? Ther Adv Respir Dis 2008;2(2):65–74.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    1. Gao F,
    2. Koenitzer JR,
    3. Tobolewski JM,
    4. Jiang D,
    5. Liang J,
    6. Noble PW,
    7. Oury TD
    . Extracellular superoxide dismutase inhibits inflammation by preventing oxidative fragmentation of hyaluronan. J Biol Chem 2008;283(10):6058–6066.
    OpenUrlAbstract/FREE Full Text
  39. 39.
    1. Kliment CR,
    2. Tobolewski JM,
    3. Manni ML,
    4. Tan RJ,
    5. Enghild J,
    6. Oury TD
    . Extracellular superoxide dismutase protects against matrix degradation of heparan sulfate in the lung. Antioxid Redox Signal 2008;10(2):261–268.
    OpenUrlCrossRefPubMedWeb of Science
  40. 40.↵
    1. Petersen SV,
    2. Oury TD,
    3. Ostergaard L,
    4. Valnickova Z,
    5. Wegrzyn J,
    6. Thøgersen IB,
    7. et al
    . Extracellular SOD binds to type I collagen and protects against oxidative fragmentation. J Biol Chem 2004;279(14):13705–13710.
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    1. Fattman CL,
    2. Tan RJ,
    3. Tobolewski JM,
    4. Oury TD
    . Increased sensitivity to asbestos-induced lung injury in mice lacking extracellular superoxide dismutase. Free Radic Biol Med 2006;40(4):601–607.
    OpenUrlCrossRefPubMedWeb of Science
  42. 42.↵
    1. Folz RJ,
    2. Crapo JD
    . Extracellular superoxide dismutase (SOD3). Tissue specific expression, genomic characterization, and computer-assisted sequence analysis of the human EC SOD gene. Genomics 1994;22(1):162–171.
    OpenUrlCrossRefPubMedWeb of Science
  43. 43.↵
    1. Ahmed MN,
    2. Suliman HB,
    3. Folz RJ,
    4. Nozik-Grayck E,
    5. Golson ML,
    6. Mason SN,
    7. Auten RL
    . Extracellular superoxide dismutase protects lung development in hyperoxia-exposed newborn mice. Am J Respir Crit Care Med 2003;167(3):400–405.
    OpenUrlCrossRefPubMedWeb of Science
  44. 44.
    1. Auten RL,
    2. O'Reilly MA,
    3. Oury TD,
    4. Nozik-Grayck E,
    5. Whorton MH
    . Transgenic EC superoxide dismutase protects postnatal alveolar epithelial proliferation and development during hyperoxia. Am J Physiol Lung Cell Mol Physiol 2006;290(1):L32–L40.
    OpenUrlAbstract/FREE Full Text
  45. 45.
    1. Ghio AJ,
    2. Suliman HB,
    3. Carter JD,
    4. Abushamaa AM,
    5. Folz RJ
    . Overexpression of extracellular superoxide dismutase decreases lung injury after exposure to oil fly ash. Am J Physiol Lung Cell Mol Physiol 2002;283(1):L211–L218.
    OpenUrlAbstract/FREE Full Text
  46. 46.↵
    1. Tan RJ,
    2. Fattman CL,
    3. Watkins SC,
    4. Oury TD
    . Redistribution of pulmonary EC-SOD after exposure to asbestos. J Appl Physiol 2004;97(5):2006–2013.
    OpenUrlAbstract/FREE Full Text
  47. 47.↵
    1. Oury TD,
    2. Chang LY,
    3. Marklund SL,
    4. Day BJ,
    5. Crapo JD
    . Immunocytochemical localization of extracellular superoxide dismutase in human lung. Lab Invest 1994;70(6):889–898.
    OpenUrlPubMedWeb of Science
  48. 48.↵
    1. Oury TD,
    2. Day BJ,
    3. Crapo JD
    . Extracellular superoxide dismutase in vessels and airways of humans and baboons. Free Radic Biol Med 1996;20(7):957–965.
    OpenUrlCrossRefPubMedWeb of Science
  49. 49.↵
    1. Yen CC,
    2. Lai YW,
    3. Chen HL,
    4. Lai CW,
    5. Lin CY,
    6. Chen W,
    7. et al
    . Aerosolized human extracellular superoxide dismutase prevents hyperoxia-induced lung injury. PLoS ONE 2011;6(10):e26870.
    OpenUrlCrossRefPubMed
  50. 50.↵
    1. Zeng M,
    2. Li Y,
    3. Jiang Y,
    4. Lu G,
    5. Huang X,
    6. Guan K
    . Local and systemic oxidative stress status in COPD patients. Can Respir J 2013;20(1):35–41.
    OpenUrlPubMed
  51. 51.↵
    1. Gavali Y,
    2. Deore D,
    3. Surwase SP,
    4. Zingade U
    . Study of the serum superoxide dismutase levels in smoking and non-smoking patients with COPD. Int J Recent Trends Sci Tech 2013;5(3):121–126.
    OpenUrl
  52. 52.↵
    1. Tavilani H,
    2. Nadi E,
    3. Karimi J,
    4. Goodarzi MT
    . Oxidative stress in COPD patients, smokers and non-smokers. Respir Care 2012;57(12):2090–2094.
    OpenUrlAbstract/FREE Full Text
  53. 53.↵
    1. Daga MK,
    2. Chhabra R,
    3. Sharma B,
    4. Mishra TK
    . Effects of exogenous vitamin E supplementation on levels of oxidants and antioxidants in COPD. J Biosci 2003;28(1):7–11.
    OpenUrlPubMedWeb of Science
  54. 54.↵
    1. Chakraborty I,
    2. Kunti S,
    3. Bandyopadhyay M,
    4. Dasgupta A,
    5. Chattopadhyay DG,
    6. Chakraborty S
    . Evaluation of serum zinc level and plasma SOD activity in senile cataract patients under oxidative stress. Indian J Clin Biochem 2007;22(2):109–113.
    OpenUrl
  55. 55.↵
    1. Kotur-Stevuljevic J,
    2. Spasic S,
    3. Jelic-Ivanovic Z,
    4. Spasojevic-Kalimanovska V,
    5. Stefanovic A,
    6. Vujovic A,
    7. et al
    . PON1 status is influenced by oxidative stress and inflammation in coronary heart disease patients. Clin Biochem 2008;41(13):1067–1073.
    OpenUrlCrossRefPubMedWeb of Science
  56. 56.↵
    1. Comhair SA,
    2. Lewis MJ,
    3. Bhathena PR,
    4. Hammel JP,
    5. Erzurum SC
    . Increased glutathione and glutathione peroxidase in lungs of individuals with chronic beryllium disease. Am J Respir Crit Care Med 1999;159(6):1824–1829.
    OpenUrlCrossRefPubMedWeb of Science
  57. 57.↵
    1. Kakkar P,
    2. Das B,
    3. Viswanathan PN
    . A modified spectrophotometric assay of superoxide dismutase. Indian J Biochem Biophys 1984;21(2):130–132.
    OpenUrlPubMedWeb of Science
  58. 58.↵
    1. Matés JM
    . Effects of antioxidant enzymes in the molecular control of reactive oxygen species toxicology. Toxicology 2000;153(1-3):83–104.
    OpenUrlCrossRefPubMedWeb of Science
  59. 59.
    1. Valko M,
    2. Rhodes CJ,
    3. Moncol J,
    4. Izakovic M,
    5. Mazur M
    . Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 2006;160(1):1–40.
    OpenUrlCrossRefPubMedWeb of Science
  60. 60.↵
    1. Baud O,
    2. Greene AE,
    3. Li J,
    4. Wang H,
    5. Volpe JJ,
    6. Rosenberg PA
    . Glutathione peroxidase-catalase cooperativity is required for resistance to hydrogen peroxide by mature rat oligodendrocytes. J Neurosci 2004;24(7):1531–1540.
    OpenUrlAbstract/FREE Full Text
  61. 61.↵
    1. Nadeem A,
    2. Raj HG,
    3. Chhabra SK
    . Increased oxidative stress and altered levels of antioxidants in chronic obstructive pulmonary disease. Inflammation 2005;29(1):23–32.
    OpenUrlCrossRefPubMedWeb of Science
  62. 62.↵
    1. Blum J,
    2. Fridovich I
    . Inactivation of glutathione peroxidase by superoxide radical. Arch Biochem Biophys 1985;240(2):500–508.
    OpenUrlCrossRefPubMedWeb of Science
  63. 63.↵
    1. Alegría A,
    2. Barberá R,
    3. Clemente G,
    4. Farré R,
    5. García MJ,
    6. Lagarda MJ
    . Selenium and glutathione peroxidase reference values in whole blood and plasma of a reference population living in Valencia, Spain. J Trace Elem Med Biol 1996;10(4):223–228.
    OpenUrlPubMedWeb of Science
  64. 64.↵
    1. Paglia DE,
    2. Valentine WN
    . Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967;70(1):158–169.
    OpenUrlPubMedWeb of Science
  65. 65.↵
    1. Hackett NR,
    2. Heguy A,
    3. Harvey BG,
    4. O'Connor TP,
    5. Luettich K,
    6. Flieder DB,
    7. et al
    . Variability of antioxidant-related gene expression in the airway epithelium of cigarette smokers. Am J Respir Cell Mol Biol 2003;29(3):331–343.
    OpenUrlCrossRefPubMedWeb of Science
  66. 66.↵
    1. Osaki S,
    2. Johnson DA,
    3. Frieden E
    . The possible significance of the ferrous oxidase activity of ceruloplasmin in normal human serum. J Biol Chem 1966;241(12):2746–2751.
    OpenUrlAbstract/FREE Full Text
  67. 67.↵
    1. Curzon G
    . Some properties of coupled iron ceruloplasmin oxidation systems. Biochem J 1961;79:656–663.
    OpenUrlFREE Full Text
  68. 68.↵
    1. Al-Timimi DJ,
    2. Dormandy TL
    . The inhibition of lipid autoxidation by human caeruloplasmin. Biochem J 1977;168(2):283–288.
    OpenUrlAbstract/FREE Full Text
  69. 69.↵
    1. Taylor JC,
    2. Madison R,
    3. Wong E,
    4. Mittman C
    . Do ceruloplasmin and elastase inhibition abnormalities influence the pathogenesis of COPD. Chest 1984;85(6 Suppl):45S.
    OpenUrl
  70. 70.↵
    1. Verrills NM,
    2. Irwin JA,
    3. He XY,
    4. Wood LG,
    5. Powell H,
    6. Simpson JL,
    7. et al
    . Identification of novel diagnostic biomarkers for asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011;183(12):1633–1643.
    OpenUrlCrossRefPubMedWeb of Science
  71. 71.↵
    1. Pedersen JZ,
    2. Franck C
    . Increased serum levels of ceruloplasmin in severe chronic airflow obstruction. Eur J Respir Dis 1987;70(3):140–144.
    OpenUrlPubMed
  72. 72.↵
    1. de Torres JP,
    2. Cordoba-Lanus E,
    3. López-Aguilar C,
    4. Muros de Fuentes M,
    5. Montejo de Garcini A,
    6. Aguirre-Jaime A,
    7. et al
    . C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J 2006;27(5):902–907.
    OpenUrlAbstract/FREE Full Text
  73. 73.↵
    1. Dahl M,
    2. Vestbo J,
    3. Lange P,
    4. Bojesen SE,
    5. Tybjaerg-Hansen A,
    6. Nordestgaard BG
    . C-reactive protein as a predictor of prognosis in COPD. Am J Respir Crit Care Med 2007;175(3):250–255.
    OpenUrlCrossRefPubMedWeb of Science
  74. 74.↵
    1. Akbulut HH,
    2. Ozden M,
    3. Deveci F,
    4. Muz MH
    . IL-6 and IL-8 levels in patients with acute exacerbation of chronic obstructive pulmonary disease. J Clin Diagn Res 2009;3(1):1285–1288.
    OpenUrl
  75. 75.↵
    1. van Durme YM,
    2. Verhamme KM,
    3. Aarnoudse AJ,
    4. Van Pottelberge GR,
    5. Hofman A,
    6. Witteman JC,
    7. et al
    . C-reactive protein levels, haplotypes, and the risk of incident chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;179(5):375–382.
    OpenUrlCrossRefPubMedWeb of Science
  76. 76.↵
    1. Deng ZC,
    2. Zhao P,
    3. Cao C,
    4. Sun SF,
    5. Zhao F,
    6. Lu CY,
    7. Ma HY
    . C-reactive protein as a prognostic marker in chronic obstructive pulmonary disease. Exp Ther Med 2014;7(2):443–446.
    OpenUrlPubMed
  77. 77.↵
    1. Mori K,
    2. Kurihara N,
    3. Hayashida S,
    4. Tanaka M,
    5. Ikeda K
    . The intrauterine expression of surfactant protein D in the terminal airways of human fetuses compared with surfactant protein A. Eur J Pediatr 2002;161(8):431–434.
    OpenUrlCrossRefPubMedWeb of Science
  78. 78.↵
    1. Janssen R,
    2. Sato H,
    3. Grutters JC,
    4. Bernard A,
    5. van Velzen-Blad H,
    6. du Bois RM,
    7. van den Bosch JM
    . Study of Clara cell 16, KL-6, and surfactant protein-D in serum as disease markers in pulmonary sarcoidosis. Chest 2003;124(6):2119–2125.
    OpenUrlCrossRefPubMedWeb of Science
  79. 79.↵
    1. Lomas DA,
    2. Silverman EK,
    3. Edwards LD,
    4. Locantore NW,
    5. Miller BE,
    6. Horstman DH,
    7. Tal-Singer R
    . Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. Eur Respir J 2009;34(1):95–102.
    OpenUrlAbstract/FREE Full Text
  80. 80.↵
    1. Zaky DS,
    2. Naiem M,
    3. Eid HA,
    4. Adawy ZR,
    5. Abd-Elraheem SE,
    6. Mohamed ZA
    . Circulating surfactant protein-D as a biomarker of severity in stable chronic obstructive pulmonary diseases. Egypt J Chest Dis Tuberc 2014;63(3):553–559.
    OpenUrl
  81. 81.↵
    1. Liu W,
    2. Ju CR,
    3. Chen RC,
    4. Liu ZG
    . Role of serum and induced sputum surfactant protein D in predicting the response to treatment in chronic obstructive pulmonary disease. Exp Ther Med 2014;8(4):1313–1317.
    OpenUrlPubMed
  82. 82.↵
    1. Sin DD,
    2. Leung R,
    3. Gan WQ,
    4. Man SP
    . Circulating surfactant protein D as a potential lung-specific biomarker of health outcomes in COPD: a pilot study. BMC Pulm Med 2007;7:135.
    OpenUrl
  83. 83.↵
    1. Bridges JP,
    2. Davis HW,
    3. Damodarasamy M,
    4. Kuroki Y,
    5. Howles G,
    6. Hui DY,
    7. McCormack FX
    . Pulmonary surfactant proteins A and D are potent endogenous inhibitors of lipid peroxidation and oxidative cellular injury. J Biol Chem 2000;275(49):38848–38855.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

 

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Related Articles

Cited By...

Keywords